Glucocorticoid nanolipid carrier for treating joint pain, preparation method and application

By using nanolipid carriers prepared by glucocorticoids, phospholipids and polyethylene glycol 15-hydroxystearate, the preparation of glucocorticoid drugs in the prior art is solved by short analgesic effects and polymer sustained release microspheres in the preparation of polymers in the prior art Complex problems have achieved long-term analgesia, high safety and simple process therapeutic effects.

CN116077669BActive Publication Date: 2024-11-15XIANGYA HOSPITAL CENT SOUTH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211617076.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-15
Publication Date
2024-11-15
Estimated Expiration
2042-12-15

AI Technical Summary

Technical Problem

When existing glucocorticoid drugs are used to treat osteoarthritis, the analgesic effect is maintained for a short time, the preparation process of polymer sustained-release microspheres is complex and has safety risks, which may promote inflammatory response.

Method used

Using nanolipid carriers composed of glucocorticoids, phospholipids and 15-hydroxystearate polyethylene glycol ester, a nanolipid carrier with good physical and chemical stability is formed through specific mass ratios and preparation processes for treatment. Joint pain.

Benefits of technology

It achieves long-term analgesic effects, improves the retention time and safety of drugs, simplifies the preparation process, and reduces the amount of drugs used, significantly improving the retention time and therapeutic effect of drugs in the joint cavity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116077669B_ABST
    Figure CN116077669B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a glucocorticoid nanolipid carrier, a preparation method and an application for treating arthralgia. The raw materials for preparing the glucocorticoid nanolipid carrier include glucocorticoid, phospholipid and 15-hydroxystearic acid polyethylene glycol ester, and the mass ratio of the glucocorticoid, phospholipid and 15-hydroxystearic acid polyethylene glycol ester is 0.5-20:20-140:10-200. The beneficial effects of the present invention are as follows: the present invention can prepare a glucocorticoid nanolipid carrier with long-acting analgesia and good analgesic effect by using glucocorticoid, phospholipid and 15-hydroxystearic acid polyethylene glycol ester as raw materials, and the process is simple and feasible, the controllability is strong, and continuous batch production can be achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a glucocorticoid nanolipid carrier for treating joint pain, a preparation method and an application thereof. Background Art

[0002] Osteoarthritis (OA) is an aging disease caused by multiple factors with joint pain as the main symptom. Analgesia is the main demand of OA patients for medical treatment. Glucocorticoid (GC) is a class of steroidal small molecule drugs with diverse pharmacological effects. It can exert analgesic effects by inhibiting inflammatory responses and has been widely used for OA analgesia; however, GC has important problems that need to be solved, such as a short duration of analgesic effect, insufficient effect, and potential safety hazards. For example, the clinically used triamcinolone acetonide immediate-release suspension injection has an average retention time of 3.8 days in the knee joint of patients with osteoarthritis, and the frequency of joint cavity injection is high. Therefore, it is of great significance to reduce the frequency of GC administration and prolong its analgesic effect in osteoarthritis.

[0003] In recent years, with the widespread application of biopolymer materials in the field of medicine, sustained-release microspheres based on polymers have gradually become one of the research hotspots of new drug preparations. At present, the polymer sustained-release microspheres on the market are mainly polylactic acid-glycolic acid (PLGA) sustained-release microspheres. Encapsulating GC (such as triamcinolone acetonide, dexamethasone, dexamethasone palmitate, etc.) in PLGA microspheres and injecting them into the joint cavity can prolong the analgesic effect of GC on OA, but the retention time and analgesic time of the drug in the joint cavity are related to the particle size of the microspheres. When the particle size of the microspheres is greater than 25μm, there is a risk of promoting the development of joint inflammation. In addition, the preparation process of PLGA sustained-release microspheres is complicated, terminal sterilization is difficult, and the lactic acid and glycolic acid produced during the degradation process may cause the pH in the joint cavity to decrease, thereby promoting the development of inflammatory response. Summary of the invention

[0004] The purpose of the present invention is to provide a glucocorticoid nanolipid carrier for treating joint pain, which has long-lasting analgesic effect, good analgesic effect, stable quality and high safety, and a preparation method and application thereof in view of the above-mentioned problems existing in the prior art.

[0005] The invention provides a glucocorticoid nanolipid carrier for treating joint pain. The preparation raw materials thereof include glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol ester. The mass ratio of the glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol ester is 0.5-20:20-140:10-200.

[0006] The present invention particularly adopts the liposome membrane material composed of phospholipid and 15-hydroxystearic acid polyethylene glycol ester, phospholipid is the basis of liposome membrane structure, 15-hydroxystearic acid polyethylene glycol ester has lipophilic groups and polyethylene glycol hydrophilic groups including polyethylene glycol monoester and 15-hydroxystearic acid, thus has certain emulsification. When single phospholipid is used for preparation, the obtained solution has poor transmittance, and obvious drug crystals appear, and when phospholipid and 15-hydroxystearic acid polyethylene glycol ester are added at the same time, nano lipid carrier with good physicochemical stability can be prepared. Preferably, the mass ratio of described glucocorticoid, phospholipid and 15-hydroxystearic acid polyethylene glycol ester is 2-5:20-140:10-200, more preferably 4:140:70.

[0007] The phospholipids in the present invention can be selected from conventional raw materials, including but not limited to natural phospholipids (such as egg yolk lecithin, soybean lecithin), hydrogenated lecithin, synthetic phospholipids (such as phosphatidylethanolamine, phosphatidylcholine, etc.), preferably lecithin. The glucocorticoid may be selected from clobetasol propionate, diflorasone acetate, dexamethasone propionate, difluprednate, mometasone furoate, diflucortolone valerate, betamethasone butyrate propionate, fluocinolone acetate, hydrocortisone propionate butyrate, beclomethasone propionate, deproton propionate, betamethasone valerate, dexamethasone valerate, prednisolone acetate valerate, fluocinolone, hydrocortisone butyrate, clobetasone butyrate, alclomethasone propionate, triamcinolone acetonide, triamcinolone acetonide acetate, flumethasone pivalate, prednisolone, hydrocortisone, dexamethasone, dexamethasone acetate, dexamethasone palmitate, one or more of triamcinolone acetonide palmitate, preferably triamcinolone acetonide, dexamethasone or a pharmaceutically acceptable salt or acetylate or palmitate thereof. The salts include, but are not limited to, salts of inorganic acids and organic acids. Inorganic acids include, but are not limited to, hydrochloric acid, sulfuric acid, and nitric acid. Organic acids include, but are not limited to, acetic acid (i.e., acetic acid), citric acid, lactic acid, and formic acid.

[0008] The preparation method of the aforementioned glucocorticoid nanolipid carrier of the present invention comprises the following steps: (1) dissolving glucocorticoid, phospholipid and 15-hydroxystearic acid polyethylene glycol ester in an organic solvent, and then removing the organic solvent to obtain a mixture; (2) hydrating the mixture with an aqueous medium, and then performing ice-water bath probe ultrasound to obtain; in step (1), the organic solvent includes but is not limited to chloroform, acetone, dichloromethane, methanol, preferably chloroform and / or acetone, and the organic solvent is removed by vacuum rotary evaporation; in step (2), the aqueous medium is pure water or a buffer solution, and the buffer solution includes a phosphate buffer solution and a physiological saline solution, preferably a physiological saline solution, and the ice-water bath probe ultrasound preferably has a power of 300 W and a time of 5 min.

[0009] Based on the aforementioned glucocorticoid nanolipid carrier of the present invention, a lyophilized powder injection can be further prepared by a conventional freeze-drying method.

[0010] The preparation method of the aforementioned glucocorticoid nanolipid carrier of the present invention has optimized the preparation process and parameters, thereby forming the final preparation method, 1) the average particle size of the prepared nanolipid carrier is 100-150 nm, and the drug efficacy is better at the same dose, so the same therapeutic effect is achieved, the amount of drug used will be less, the safety is higher, and the process is simple and feasible, the controllability is strong, and continuous batch production can be achieved; 2) The joint cavity retention experiment found that the polymer nanocarriers prepared by different materials, even if the particle size is similar, the retention time in the joint cavity of the OA model rat is much shorter than the retention time of the nanolipid carrier prepared by the present invention in the joint cavity of the OA model rat; the pharmacodynamics experiment found that the mechanical foot retraction threshold of the aforementioned polymer nanocarrier on the 35th day and the ratio of the weight difference of the two feet on the 35th day / the weight of the modeling hind limbs are significantly lower than the nanolipid carrier of the present invention. The above results confirm that the preparation method defined by the present invention is conducive to the preparation of glucocorticoid nanolipid carriers with longer-lasting analgesia and better analgesic effect.

[0011] The aforementioned glucocorticoid nanolipid carrier of the present invention can be made into a drug for treating joint pain, which can effectively solve the problems of short duration of analgesic effect of existing glucocorticoid drugs, or complex preparation process of polymer material sustained-release preparations and safety risks caused by material degradation.

[0012] The beneficial effects of the present invention are:

[0013] The present invention adopts glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol ester as raw materials to prepare glucocorticoid nano lipid carrier with long-acting analgesic effect, good analgesic effect, stable quality and high safety, and the process is simple and feasible, the controllability is strong, and continuous batch production is possible. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1A : Relative expression of mRNA encoding TNF-α gene in cells;

[0015] Figure 1B : Relative expression of mRNA encoding IL-1β gene in cells;

[0016] Figure 1C : Relative expression of mRNA encoding IL-6 gene in cells;

[0017] Figure 1D : Relative expression of mRNA encoding IL-4 gene in cells;

[0018] Figure 1E: Relative expression of mRNA encoding IL-10 gene in cells;

[0019] Figure 1F : Relative expression of mRNA encoding iNOS gene in cells;

[0020] Figure 2 : Experimental results of intra-articular distribution of samples in each group (n=3);

[0021] Figure 3A : Changes in mechanical withdrawal threshold of right hind limbs in OA model rats (n=7);

[0022] Figure 3B : Changes in the ratio of the weight difference between the two feet of OA model rats to the weight of the modeling hind limbs (n=7);

[0023] Figure 4A : Changes in mechanical withdrawal threshold of right hind limbs in OA model rats (n=7);

[0024] Figure 4B : Changes in the ratio of the weight-bearing difference between the two feet of OA model rats to the weight of the modeled hind limbs (n=7). DETAILED DESCRIPTION

[0025] To make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described in detail below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other implementation methods obtained by ordinary technicians in this field without creative work belong to the scope of protection of the present invention.

[0026] Example 1

[0027] 4 mg of triamcinolone acetonide, 140 mg of phospholipid E80, and 70 mg of 15-hydroxystearate polyethylene glycol ester (HS15) were dissolved in 100 mL of chloroform. The chloroform was removed by vacuum rotary evaporation at 40 °C, and 4 mL of normal saline was added for hydration. The mixture was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain triamcinolone acetonide nanolipid carrier with a particle size of 103 nm.

[0028] Example 2

[0029] 2 mg of triamcinolone acetonide, 100 mg of phospholipid E80, and 10 mg of HS15 were dissolved in 50 mL of chloroform. The chloroform was removed by vacuum rotary evaporation at 40 °C, and 4 mL of normal saline was added for hydration. The triamcinolone acetonide nanolipid carrier was obtained by ultrasonication with an ice-water bath probe (300 W, 5 min) with a particle size of 140 nm.

[0030] Example 3

[0031] 4 mg of triamcinolone acetonide, 20 mg of phospholipid E80, and 200 mg of HS15 were dissolved in 50 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the mixture was ultrasonicated in an ice-water bath (300 W, 5 min) to obtain triamcinolone acetonide nanolipid carrier with a particle size of 123 nm.

[0032] Example 4

[0033] 3 mg of triamcinolone acetonide acetate, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 100 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the mixture was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain triamcinolone acetonide acetate nanolipid carrier with a particle size of 110 nm.

[0034] Example 5

[0035] 0.5 mg of triamcinolone acetonide, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 100 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the mixture was ultrasonicated in an ice-water bath (300 W, 5 min) to obtain triamcinolone acetonide nanolipid carrier with a particle size of 93 nm.

[0036] Example 6

[0037] 10 mg of triamcinolone acetonide, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 500 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the triamcinolone acetonide nanolipid carrier was obtained by ultrasonication with an ice-water bath probe (300 W, 5 min) with a particle size of 123 nm.

[0038] Example 7

[0039] 15 mg of triamcinolone acetonide acetate, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 300 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the mixture was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain triamcinolone acetonide acetate nanolipid carrier with a particle size of 142 nm.

[0040] Example 8

[0041] 5 mg of dexamethasone, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 50 mL of chloroform-acetone mixed solution, and the organic reagent was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the solution was sonicated in an ice-water bath probe (300 W, 5 min) to obtain a dexamethasone nanolipid carrier with a particle size of 118 nm.

[0042] Example 9

[0043] 5 mg of dexamethasone palmitate, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 100 mL of chloroform-acetone mixed solution, and the organic reagent was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the solution was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain a dexamethasone palmitate nanolipid carrier with a particle size of 121 nm.

[0044] Example 10

[0045] 20 mg of dexamethasone palmitate, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 200 mL of chloroform-acetone mixed solution, and the organic reagent was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the solution was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain a dexamethasone palmitate nanolipid carrier with a particle size of 158 nm.

[0046] Embodiment 11

[0047] 5 mg of dexamethasone acetate, 140 mg of phospholipid E80, and 70 mg of HS15 were dissolved in 100 mL of chloroform-acetone mixed solution, and the organic reagent was removed by vacuum rotary evaporation at 40 °C. 4 mL of normal saline was added for hydration, and the solution was ultrasonicated with an ice-water bath probe (300 W, 5 min) to obtain a dexamethasone acetate nanolipid carrier with a particle size of 128 nm.

[0048] Examples 12 to 22

[0049] The preparation of the freeze-dried powder injection of the present invention comprises taking the glucocorticoid nanolipid carrier prepared in Examples 1 to 11 and freeze-drying it to obtain the freeze-dried powder injection.

[0050] Comparative Example 1

[0051] 3 mg of triamcinolone acetonide and 210 mg of phospholipid E80 were dissolved in 100 mL of chloroform. The chloroform was removed by vacuum rotary evaporation at 40 °C, and 4 mL of normal saline was added for hydration. After ultrasonic treatment with an ice-water bath probe (300 W, 5 min), the solution had poor transmittance and obvious drug crystals appeared.

[0052] Comparative Example 2

[0053] 3 mg of triamcinolone acetonide acetate and 210 mg of phospholipid E80 were dissolved in 100 mL of chloroform. The chloroform was removed by vacuum rotary evaporation at 40 °C, and 4 mL of normal saline was added for hydration. After ultrasonic treatment with an ice-water bath probe (300 W, 5 min), the solution had poor transmittance and obvious drug crystals appeared.

[0054] Comparative Example 3

[0055] 5 mg of triamcinolone acetonide, 10 mg of phospholipid E80, and 200 mg of HS15 were dissolved in 100 mL of chloroform. The chloroform was removed by vacuum rotary evaporation at 40 °C, and 4 mL of normal saline was added for hydration. After ultrasonic treatment with an ice-water bath probe (300 W, 5 min), the solution had good transmittance, but drug crystals precipitated within 10 min.

[0056] Comparative Example 4

[0057] 2 mg of triamcinolone acetonide, 800 mg of phospholipid E80, and 1 mg of HS15 were dissolved in 50 mL of chloroform, and the chloroform was removed by vacuum rotary evaporation at 40 °C. 16 mL of normal saline was added for hydration, and triamcinolone acetonide nanolipid carriers were obtained after high-pressure homogenization with a particle size of 145 nm. Due to the low proportion of HS15, the retention time of the nanolipid carrier in the joint was significantly shortened.

[0058] Comparative Example 5

[0059] 2 mg triamcinolone acetonide and 200 mg PLGA50 / 50 (average molecular weight 40,000) were dissolved in a dichloromethane-acetone mixed solution to prepare an organic phase; PVA was dissolved in water to prepare a 1% mass-volume concentration PVA aqueous solution as the aqueous phase; the two phases were mixed according to the organic phase / aqueous phase volume ratio of 1:10, probe ultrasound was performed in an ice water bath (300 W, 8 min), and the organic reagent was removed by a rotary evaporator to obtain a triamcinolone acetonide polymer nanocarrier with a particle size of 156 nm. This nanocarrier can successfully encapsulate glucocorticoids (such as triamcinolone acetonide), but its retention time in the joint is short, so its analgesic effect on OA is also poor.

[0060] Comparative Example 6

[0061] 2 mg dexamethasone and 200 mg PLGA50 / 50 (average molecular weight 40,000) were dissolved in a dichloromethane-acetone mixed solution to prepare an organic phase; PVA was dissolved in water to prepare a 1% mass-volume concentration of PVA aqueous solution as the aqueous phase; the two phases were mixed according to the organic phase / aqueous phase volume ratio of 1:10, probe ultrasound was performed in an ice water bath (300 W, 8 min), and the organic reagent was removed by a rotary evaporator to obtain a dexamethasone polymer nanocarrier with a particle size of 151 nm. This nanocarrier can successfully encapsulate glucocorticoids (such as dexamethasone), but its retention time in the joint is short, so its analgesic effect on OA is also poor.

[0062] Comparative Example 7

[0063] 4 mg dexamethasone, 1000 mg phospholipid E80, and 1 mg HS15 were dissolved in 50 mL chloroform-acetone mixture, chloroform was removed by vacuum rotary evaporation at 40°C, 20 mL normal saline was added for hydration, and dexamethasone nanolipid carriers were obtained after high pressure homogenization with a particle size of 149 nm. Due to the low proportion of HS15, the inhibitory effect of the nanolipid carrier on joint inflammation and pain in OA rats was significantly reduced.

[0064] Experimental Example 1 Investigation of in vitro biological activity

[0065] Mouse macrophages RAW264.7 were inoculated in a 12-well cell culture plate. After they adhered to the wall, they were stimulated with lipopolysaccharide for 24 h. The culture medium was replaced with a drug-containing (triamcinolone acetonide solution or triamcinolone acetonide nanolipid carrier of Example 1) culture medium, which were recorded as the solution group and the nanolipid carrier group (the concentration of triamcinolone acetonide was 4 μg / mL, and the culture medium without drug was used as the control). After incubation for 24 h, the concentrations of IL-1β, TNF-α, IL-6, IL-10, IL-4 and iNOS were determined by real-time fluorescence quantitative PCR. Cells not treated with lipopolysaccharide and cells treated with lipopolysaccharide but not treated with triamcinolone acetonide were recorded as the "control group" and the "lipopolysaccharide group", respectively. The results are shown in Figure 1A-1F (*P<0.05, **P<0.01, ***P<0.001).

[0066] Depend on Figure 1A-1F It can be seen that compared with other treatment methods, triamcinolone acetonide nanolipid carrier treatment can significantly reduce the expression of macrophage inflammatory factor genes.

[0067] Experimental Example 2 Joint Cavity Retention Experiment

[0068] An OA rat model was constructed by injecting sodium iodoacetate into the articular cavity of the knee joint of SD rats. When the rat knee joint swells and the pain threshold is significantly reduced, an OA rat model is obtained. Glucocorticoids were replaced by the fluorescent marker DiD, and nanocarriers were prepared according to Example 1, Example 2, Example 3, Comparative Example 4 and Comparative Example 5. The nanocarriers prepared by DiD solution, Comparative Example 4, Comparative Example 5, Example 1, Example 2 and Example 3 were respectively injected into the knee joint cavity of OA rats (the dose of DiD in each joint cavity was 3 μg), and were respectively recorded as DiD solution group, control nanolipid carrier group, polymer nanocarrier group, nanolipid carrier group 1, nanolipid carrier group 2 and nanolipid carrier group 3. The fluorescence intensity of the inflammatory joints of the rats was examined by a small animal in vivo imaging device on 0 d, 1 d, 2 d, 3 d, 7 d, 14 d, 21 d and 28 d. The results are shown in Figure 2 .

[0069] Depend on Figure 2It can be seen that, compared with the DiD solution, the nanolipid carrier prepared by the present invention can be retained in the joint cavity of the OA model rat for at least 28 days. These results show that the nanolipid carrier of the present invention has good sustained release in the inflammatory joint cavity.

[0070] Experimental Example 3 Pharmacodynamics Experiment

[0071] An OA rat model was constructed by injecting sodium iodoacetate into the articular cavity of the knee joint of SD rats. When the rat knee joint swells and the pain threshold is significantly reduced, an OA rat model is obtained. The OA model rats were treated with normal saline, triamcinolone acetonide injection (purchased from Kunming Jida Pharmaceutical Co., Ltd.) and triamcinolone acetonide-loaded nanocarriers prepared by Comparative Example 5 and Example 1 by articular cavity injection, respectively, and were recorded as normal saline group, triamcinolone acetonide injection group, triamcinolone acetonide polymer nanocarrier group and triamcinolone acetonide nanolipid carrier group, respectively; in addition, an equal volume of normal saline was injected into the knee joint cavity of normal rats as the normal group. The dosage of triamcinolone acetonide was 60 μg per knee joint, and it was administered on the 7th day after modeling, for a total of 1 administration. Starting from the first day of administration, the mechanical foot withdrawal threshold and the difference in weight bearing between the two feet of each group of rats were measured once a week. The results are shown in Figure 3A , Figure 3B .

[0072] Depend on Figure 3A , Figure 3B It can be seen that, compared with other methods, triamcinolone acetonide nano lipid carrier treatment can more effectively relieve joint inflammation and pain in OA rats. It can be seen that the nano lipid carrier prepared by the present invention has a good application prospect in the preparation of drugs for osteoarthritis joint analgesia.

[0073] Experimental Example 4 Pharmacodynamics Experiment

[0074] An OA rat model was constructed by injecting sodium iodoacetate into the articular cavity of the knee joint of SD rats. When the rat knee joint swells and the pain threshold is significantly reduced, an OA rat model is obtained. The OA model rats were treated with normal saline and the dexamethasone nanocarriers prepared by Comparative Example 6, Comparative Example 7, and Example 8 by articular cavity injection, respectively, and were recorded as normal saline group, dexamethasone polymer nanocarrier group, dexamethasone control nanolipid carrier group, and dexamethasone nanolipid carrier group, respectively; in addition, an equal volume of normal saline was injected into the knee joint cavity of normal rats as the normal group. The dosage of dexamethasone was 80 μg per knee joint, which was administered on the 7th day after modeling, for a total of 1 administration. Starting from the first day of administration, the mechanical foot withdrawal threshold and the difference in weight bearing between the two feet of each group of rats were measured once a week. The results are shown in Figure 4A , Figure 4B .

[0075] Depend on Figure 4A , Figure 4BIt can be seen that, compared with other methods, dexamethasone nanolipid carrier treatment can more effectively relieve joint inflammation and pain in OA rats. This experiment once again confirms that the glucocorticoid nanolipid carrier prepared by the present invention has a good application prospect in the preparation of drugs for osteoarthritis joint analgesia.

[0076] The above is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention, which should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. A long-acting analgesic glucocorticoid nanolipid carrier for treating joint pain, characterized in that: The preparation raw materials include glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol ester, and the mass ratio of the phospholipid to the 15-hydroxystearate polyethylene glycol ester is 20-140:10-200; Phospholipids and 15-hydroxystearate polyethylene glycol ester constitute the membrane material of the nanolipid carrier; The glucocorticoid is one or more of triamcinolone acetonide, triamcinolone acetonide acetate, and triamcinolone acetonide palmitate; The mass ratio of the glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol is 2-5:20-140:10-200.

2. The long-acting analgesic glucocorticoid nanolipid carrier for treating joint pain according to claim 1, characterized in that: The mass ratio of the glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol is 4:140:

70.

3. The long-acting analgesic glucocorticoid nanolipid carrier for treating joint pain according to claim 1, characterized in that: The phospholipid is lecithin.

4. The method for preparing the long-acting analgesic glucocorticoid nanolipid carrier for treating joint pain according to any one of claims 1 to 3, characterized in that: The steps include: (1) dissolving glucocorticoid, phospholipid and 15-hydroxystearate polyethylene glycol in an organic solvent, and then removing the organic solvent to obtain a mixture; (2) Add an aqueous medium to the mixture for hydration, and then perform ultrasonication in an ice-water bath to obtain the product.

5. The method for preparing a long-acting analgesic glucocorticoid nanolipid carrier for treating arthralgia according to claim 4, characterized in that: In step (1), the organic solvent is chloroform and / or acetone; and / or, the organic solvent is removed by vacuum rotary evaporation.

6. The method for preparing a long-acting analgesic glucocorticoid nanolipid carrier for treating arthralgia according to claim 4, characterized in that: In step (2), the aqueous medium is physiological saline; and / or the power of the ice-water bath probe ultrasound is 300 W and the time is 5 min.

7. A glucocorticoid nanolipid carrier freeze-dried powder injection for treating joint pain, characterized in that: The nano-lipid carrier is prepared by freeze-drying the long-acting analgesic glucocorticoid nano-lipid carrier for treating joint pain as described in any one of claims 1 to 3.

8. Use of the long-acting analgesic glucocorticoid nanolipid carrier for treating arthralgia according to any one of claims 1 to 3 in the preparation of a medicament for treating arthralgia.